JAMA Network March 13, 2024
Rita Rubin

People with European genetic ancestry represent only a minority of the world’s population, yet they account for more than 90% of participants in large genomics studies.

That discrepancy “has led to many challenges in equity,” 31 leaders of the National Institutes of Health (NIH) and its All of Us Research Program noted in a recent commentary in Nature Medicine.

With the aim of improving precision medicine for all, the NIH launched All of Us in 2018. So far, All of Us has enrolled more than 750 000 people from all over the US toward its goal of 1 million or more participants. In late 2023, the program began enrolling young children at a few of its partner sites as well as...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Patient / Consumer, Pharma / Biotech, Precision Medicine
Revolutionizing Primary Care: The Role of Pharmacogenomics and AI in Personalized Medicine
BioAro Announces Real Time DNA Decoding Technology
23andMe: What If …
23andMe CEO Anne Wojcicki considers taking company private
Age of Opportunity: Artificial Intelligence and the Precision Medicine Future

Share This Article